Bristol-Myers Squibb (BMY) said Friday it received European Commission approval for the perioperative regimen of neoadjuvant Opdivo and chemotherapy followed by surgery and adjuvant Opdivo to treat resectable non-small cell lung cancer.
The approval covers treatment of cancer at high risk of recurrence in adult patients whose tumors have PD-L1 expression greater than or equal to 1%, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.